Sulzer Medica launches heart valve outside US:
This article was originally published in Clinica
Sulzer Medica is to launch its Carbomedics prosthetic mitral heart valve, SuMit, in western Europe, Canada and Japan after the successful outcome of clinical programmes. The Swiss company's cardiac surgery company, Sulzer Carbomedics began a controlled-release clinical programme in the UK, Denmark, France, Germany and Canada after attaching the CE mark in 1998. The valve can be used in ventricular hypertrophy, repeat mitral valve replacements, double valve procedures and surgery on small left ventricles. The mechanical heart valve market, excluding the US, is valued at around $254 million.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.